National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Vedolizumab (Entyvio®) in Crohn’s Disease

Vedolizumab (Entyvio®) indicated for the treatment of adult patients with moderately toseverely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist.

Rapid Review

Commenced Completed Outcome
12/09/2014 01/10/2014 Full Pharmacoeconomic Evaluation Recommended

Pharmacoeconomic Evaluation

Commenced Completed Outcome
02/04/2015  13/11/2015 Reimbursement not recommended at submitted price


The HSE has approved reimbursement following confidential price negotiations October 2017.